PAVmed Inc
PAVM0.527USD
+0.001+0.23%
Horário de mercado （ET）Cotações atrasadas em 15 min
8.83MValor de mercado
0.12P/L TTM
Mais detalhes de PAVmed Inc Empresa
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is focused on enhanced personalized cancer care through remote patient monitoring using implantable vascular access port with wireless communication combined with an oncologist-designed remote digital healthcare platform.
Informações da empresa
Código da empresaPAVM
Nome da EmpresaPAVmed Inc
Data de listagemJul 27, 2016
CEODr. Lishan Aklog, M.D.
Número de funcionários39
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 27
Endereço360 Madison Avenue
CidadeNEW YORK
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal10017
Telefone12129494319
Sitehttps://pavmed.com/
Código da empresaPAVM
Data de listagemJul 27, 2016
CEODr. Lishan Aklog, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael J. Glennon
Mr. Michael J. Glennon
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
81.67K
--
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
78.72K
--
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
65.00K
--
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
President, Chief Financial Officer
President, Chief Financial Officer
50.83K
--
Mr. Sundeep Agrawal, M.D.
Mr. Sundeep Agrawal, M.D.
Director
Director
12.20K
--
Mr. Michael A. Gordon
Mr. Michael A. Gordon
General Counsel, Secretary
General Counsel, Secretary
--
--
Ms. Debra J. White
Ms. Debra J. White
Independent Director
Independent Director
--
--
Mr. Timothy (Tim) Baxter
Mr. Timothy (Tim) Baxter
Independent Director
Independent Director
--
--
Mr. Matt Riley
Mr. Matt Riley
Director of Investor Relations
Director of Investor Relations
--
--
Mr. Shaun M. O'Neil
Mr. Shaun M. O'Neil
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael J. Glennon
Mr. Michael J. Glennon
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
81.67K
--
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
78.72K
--
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
65.00K
--
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
President, Chief Financial Officer
President, Chief Financial Officer
50.83K
--
Mr. Sundeep Agrawal, M.D.
Mr. Sundeep Agrawal, M.D.
Director
Director
12.20K
--
Mr. Michael A. Gordon
Mr. Michael A. Gordon
General Counsel, Secretary
General Counsel, Secretary
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Tasso Partners, LLC
14.61%
First Manhattan Co. LLC
4.05%
Dubreville (Anthony Michael)
3.44%
Pavilion Venture Partners, L.L.C.
1.69%
Geode Capital Management, L.L.C.
0.53%
Other
75.68%
Investidores
Investidores
Proporção
Tasso Partners, LLC
14.61%
First Manhattan Co. LLC
4.05%
Dubreville (Anthony Michael)
3.44%
Pavilion Venture Partners, L.L.C.
1.69%
Geode Capital Management, L.L.C.
0.53%
Other
75.68%
Tipos de investidores
Investidores
Proporção
Corporation
16.31%
Individual Investor
5.92%
Investment Advisor
5.88%
Investment Advisor/Hedge Fund
0.72%
Hedge Fund
0.19%
Research Firm
0.14%
Venture Capital
0.13%
Other
70.72%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
101
5.16M
29.28%
+2.77M
2025Q1
106
5.16M
31.74%
+3.03M
2024Q4
110
2.41M
17.67%
+156.53K
2024Q3
120
2.58M
24.42%
+197.13K
2024Q2
133
1.94M
20.61%
-301.78K
2024Q1
169
2.19M
26.52%
+433.78K
2023Q4
185
1.60M
20.86%
-48.73K
2023Q3
208
1.30M
18.00%
-268.87K
2023Q2
221
1.26M
18.65%
-731.24K
2023Q1
227
1.31M
20.36%
-649.18K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Tasso Partners, LLC
2.57M
14.61%
+2.57M
--
Feb 21, 2025
First Manhattan Co. LLC
714.10K
4.05%
+14.10K
+2.01%
Mar 31, 2025
Dubreville (Anthony Michael)
606.26K
3.44%
+606.26K
--
Aug 30, 2024
Pavilion Venture Partners, L.L.C.
297.11K
1.69%
--
--
Apr 22, 2025
Geode Capital Management, L.L.C.
92.67K
0.53%
+13.20K
+16.62%
Mar 31, 2025
Glennon (Michael J)
81.67K
0.46%
+1.00
+0.00%
Apr 22, 2025
The Vanguard Group, Inc.
81.49K
0.46%
--
--
Mar 31, 2025
Aklog (Lishan)
78.72K
0.45%
--
--
Apr 22, 2025
BlackRock Institutional Trust Company, N.A.
72.66K
0.41%
--
--
Mar 31, 2025
CAPTRUST Financial Advisors
65.05K
0.37%
+65.05K
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Dec 04, 2023
Merger
15<1
Dec 04, 2023
Merger
15<1
Dec 04, 2023
Merger
15<1
Dec 04, 2023
Merger
15<1
Data
Tipo
Proporção
Dec 04, 2023
Merger
15<1
Dec 04, 2023
Merger
15<1
Dec 04, 2023
Merger
15<1
Dec 04, 2023
Merger
15<1
